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Abstract
Chronic inflammation and persistent oxidative stress contribute to the development and
progression of vascular proliferative diseases. We hypothesized that the proinflammatory cytokine
interleukin (IL)-17A induces oxidative stress and amplifies inflammatory signaling in human
aortic smooth muscle cells (SMC) via TRAF3IP2-mediated NLRP3/caspase-1-dependent
mitogenic and migratory proinflammatory cytokines IL-1β and IL-18. Further, we hypothesized
that these maladaptive changes are prevented by empagliflozin (EMPA), an SGLT2 (Sodium/
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Glucose Cotransporter 2) inhibitor. Supporting our hypotheses, exposure of cultured SMC to
IL-17A promoted proliferation and migration via TRAF3IP2, TRAF3IP2-dependent superoxide
and hydrogen peroxide production, NLRP3 expression, caspase-1 activation, and IL-1β and IL-18
secretion. Furthermore, NLRP3 knockdown, caspase-1 inhibition, and pretreatment with IL-1β
and IL-18 neutralizing antibodies and IL-18BP, each attenuated IL-17A-induced SMC migration
and proliferation. Importantly, SMC express SGLT2, and pre-treatment with EMPA attenuated
IL-17A/TRAF3IP2-dependent oxidative stress, NLRP3 expression, caspase-1 activation, IL-1β
and IL-18 secretion, and SMC proliferation and migration. Importantly, silencing SGLT2
attenuated EMPA-mediated inhibition of IL-17A-induced cytokine secretion and SMC
proliferation and migration. EMPA exerted these beneficial antioxidant, anti-inflammatory, antimitogenic and anti-migratory effects under normal glucose conditions and without inducing cell
death. These results suggest the therapeutic potential of EMPA in vascular proliferative diseases.

Author Manuscript

Keywords
Hyperplasia; Inflammasome; Interleukin Converting Enzyme; Migration; Mitogenesis

1.

Introduction
Vascular proliferative diseases, including restenosis following angioplasty, intermittent
hypoxia, and atherosclerosis, are characterized by smooth muscle cell (SMC) migration and
proliferation, and are exacerbated in diabetic subjects. Persistent inflammation and oxidative
stress have been shown to play causative roles in their pathology in both diabetic and nondiabetic individuals.
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Interleukin (IL)-17A is proinflammatory cytokine that belongs to a unique IL-17 family of
cytokines. The IL-17 family consists of 6 ligands (A-F) and 5 receptors (IL-17RA-E).
Originally, T helper 17 (Th17) cells are the only cell type to express IL-17A. However, it is
now known that multiple immune and non-immune cells, including cells of cardiac origin,
express IL-17A (e.g., [1]). IL-17A plays a pathological role in various inflammatory and
autoimmune diseases, including atherosclerosis and restenosis. However, published reports
have indicated either a causal role or a protective effect for this unique cytokine in the
pathophysiology of atherosclerosis. For example, it’s increased expression has been shown
to promote a more fibrous and stable plaque in a preclinical mouse model [2], demonstrating
that IL-17 is atheroprotective. In contrast, a positive correlation was identified between its
enhanced expression and inflammation and plaque vulnerability in humans [3], suggesting
that its expression is proatherogenic. Recently, it has also been shown that targeting the
IL-17RA pathway normalizes arterial inflammation even in advanced atherosclerosis in a
preclinical model [4], suggesting again a proatherogenic role for IL-17A.
IL-17 signals predominantly via TRAF3IP2 [(TRAF3 Interacting protein 2, also known as
CIKS (Connection to IKK and SAPK/JNK) or Act1 (Nuclear Factor NF-Kappa-B Activator
1)], a cytoplasmic adapter molecule. We have previously reported that IL-17A promotes
migration and proliferation of human primary aortic SMC in a TRAF3IP2-dependent
manner [5]. We have also reported that oxidative stress plays a role in TRAF3IP2 induction
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[6–8]. Interestingly, TRAF3IP2 also increases oxidative stress, as evidenced by the increased
generation of superoxide and hydrogen peroxide in cells of cardiac and renal origin in
response to various stressors, including high glucose, cytokines, angiotensin II and
aldosterone [8–11]. More importantly, deletion of TRAF3IP2 in ApoE knockout mice blunts
the development of atherosclerosis [12], a known contributor to myocardial injury,
inflammation, and heart failure. In fact, TRAF3IP2 deletion blunts ischemia/reperfusioninduced oxidative stress, inflammation, myocardial injury, and heart failure development
[13]. These reports thus indicate a causal role for TRAF3IP2 in atherosclerotic and other
cardiovascular diseases.

Author Manuscript
Author Manuscript

Recently, several clinical trials have reported the cardiovascular protective effects of the
SGLT2 (Sodium/Glucose Cotransporter 2; also known as SLC5A2 for Solute Carrier Family
5 Member 2) inhibitors empagliflozin (EMPA), canagliflozin, and dapagliflozin [14] [15]
[16]. A majority of their protective effects have been ascribed to their blood sugar lowering
properties independent of insulin [17]. In fact, SGLT2 transcripts are expressed mainly in
proximal tubular epithelial cells in the S1 segment of the kidney ([18]), where SGLT2 plays
a major role in glucose reabsorption, and thus in glucose homeostasis. However, the
expression of SGLT2 has also been reported in other tissues and cell types. For example,
epicardial adipose tissue (EAT) from subjects with cardiovascular diseases expresses SGLT2
and responds to dapagliflozin treatment ex vivo as measured by reduced glucose uptake and
inflammatory cytokine expression [19], suggesting a functional role for SGLT2 in EAT. In
the same study [19], it has also been reported that SGLT2 inhibitor treatment of
differentiated stromal vascular cells from fat pads enhances glucose uptake, indicating
SGLT2 expression in stromal vascular cells. SGLT2 expression has also been reported in
isolated cultured rat mesangial cells [20]. Aortic SMC also express SGLT2, albeit at a lower
level than in kidney [21]. These reports suggest that cell types other than proximal tubular
epithelial cells, such as aortic SMC, are direct targets of SGLT2 inhibitors and contribute to
some of their non-glycemic vascular protective effects.

Author Manuscript

Since administration of EMPA exerts pleiotropic antioxidant and anti-inflammatory effects
that are independent of its anti-hyperglycemic effects, and since IL-17A is a potent prooxidant and proinflammatory cytokine, we investigated whether EMPA blunts IL-17Ainduced TRAF3IP2/oxidative stress-dependent proliferation and migration of cultured
primary human aortic SMC under normal glucose conditions. Further, since IL-1β and IL-18
exert mitogenic and migratory effects [22] [23] [24]) we investigated their role in IL-17induced SMC proliferation and migration, and inhibition by EMPA. Since both IL-1β and
IL-18 are synthesized as inactive precursors and cleaved by caspase-1 into biologically
active forms [25], we also determined whether EMPA negatively affects caspase-1
expression and activation. Previously, EMPA was shown to inhibit NLRP3 (Nucleotidebinding domain and Leucine-rich repeat containing Family Pyrin Domain Containing 3)
expression in liver and kidney, but not heart, in a murine model of diet-induced obesity and
insulin resistance ([26]). Since the NLRP3 inflammasome forms a molecular platform for
recruitment and activation of pro-caspase-1 to caspase-1 [27], we also determined whether
EMPA inhibits NLRP3 expression.
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Indeed, our results demonstrate that SMC express SGLT2, but at a lower level compared to
human kidney and human proximal tubule epithelial cell line, and its expression is induced
by IL-17A in a time-dependent manner. Moreover, pretreatment with the SGLT2 inhibitor
EMPA inhibits SMC proliferation and migration by targeting IL-17A/TRAF3IP2-dependent
superoxide and hydrogen peroxide generation, NLRP3 expression, caspase-1 activation, and
the release of mitogenic and migratory IL-1β and IL-18, all in the presence of normal
glucose and without inducing cell death. Importantly, silencing EMPA attenuates, but not
abrogates, IL-17A-induced cytokine expression and SMC proliferation and migration.
Together, these results further support the growing evidence of pleiotropic protective effects
of EMPA and suggest its therapeutic potential in vascular proliferative diseases.

2.
Author Manuscript

2.1.

Materials and methods
Reagents
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Empagliflozin (EMPA; 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene; #S8022) was purchased from Selleckchem (Houston, TX). MCC950
(#S8930; 10μM in ethanol for 1 h), a selective NLRP3 inhibitor that does not inhibit
NLRC4, AIM2, TLR2 signaling, or priming of NLRP3 was also purchased from
Selleckchem. In initial experiments, SMC were treated with EMPA at concentrations
ranging between 0.1 to 5 μM for 15 min prior to IL-17A addition. Since significant
inhibitory effects were observed at 1μM, this concentration was used in all subsequent
experiments. In fact, pharmacokinetics revealed its Cmax to be between 0.5 and 1.11 μM at
25 and 50 mg dose, respectively ([28]). Recombinant human (rh) IL-17A protein, carrierfree (#317-ILB), human/primate IL-17/IL-17A neutralizing antibodies (Monoclonal Mouse
IgG2B; #MAB317–100), mouse IgG2B isotype control (#MAB004), monoclonal mouse antihuman IL-1beta/IL-1F2 neutralizing antibodies (MAB601), monoclonal mouse anti-human
IL-18/IL-1F4 neutralizing antibodies (D044–3), polyclonal goat anti-human IL-18/IL-1F4
propeptide antibody (#AF646; 0.5μg/ml), anti-human IL-18 antibody (#D043–3; 0.5μg/ml)
that specifically detects mature IL-18, goat polyclonal IL-17RA neutralizing IgG antibodies
(#AF177), normal goat IgG isotype control (#AB-108-C), protein A or G purified normal
goat IgG isotype control (#AB-108-C), recombinant IL-18BPa:Fc (#119-BP), the Fc portion
of the immunoglobulin, recombinant human PDGF-BB protein, carrier-free (#220-BB), cell
permeable fluoromethyl ketone (FMK)-derivatized non-toxic Caspase-1/Interleukin
Converting Enzyme inhibitor Z-WEHD-FMK (#FMK002; 50 μM in DMSO for 30 min), the
pan-caspase inhibitor Z-VAD-FMK (#FMK001; 50 μM in DMSO for 30 min), caspase
inhibitor control Z-FA-FMK (#FMKC01; 50 μM in DMSO for 30 min), the NLRP3
inflammasome disruptor Dapansutrile (#6902; 3-(methylsulfonyl)propanenitrile; also known
as OLT1177®; 1μM in ethanol along with ATP (5mM, Millipore-Sigma) following 30 min
of IL-17A addition; [29]), Caspase-1/ICE Colorimetric Assay Kit (#K111–100), human IL-1
beta/IL-1F2 Quantikine ELISA Kit (#DLB50, sensitivity: 1 pg/ml) and human IL-18/IL-1F4
ELISA Kit (#7620, sensitivity: 12.5 pg/ml) were all purchased from R&D Systems
(Minneapolis, MN). We have previously demonstrated the functionality of these neutralizing
antibodies and IL-18BP in an in vitro cell system ([30]). Anti-IL-1β antibody (#ab9722, 0.2
μg/ml) that recognizes both proform and mature forms in Western blotting and human MIP2
ELISA Kit (CXCL2; ab184862) were bought from abcam (Cambridge, MA). Since
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rhIL-17A contained <0.10 EU/1μg of protein by the Limulus Amebocyte Lysate (LAL)
method (manufacturer’s technical data sheet), in a subset of experiments the recombinant
protein (200 ng/ml) was incubated with the endotoxin inhibitor Polymyxin B sulfate
(10μg/ml for 1 h), and SMC proliferation and migration were used as readouts. Polymyxin B
sulfate ((#BP1028), N-acetyl-L-cysteine (NAC, 5mM in water for 30 min; #A7250), Amicon
Ultra-2 Centrifugal Filter Units ($UFC200324) and other biochemicals were purchased from
Millipore-Sigma (St. Louis, MO, USA). gp91 ds-tat, a peptide inhibitor of NOX2 assembly
(YGRKKRRQRRRCSTRIRRQL- NH2; #AS-63818) and its scrambled peptide
(RKKRRQRRRCLRITRQSR-NH2; #AS-63855) were purchased from AnaSpec (Fremont,
CA), and used at a concentration of 1μM for 1 h prior to IL-17A addition as has been
previously described ([9]). The NOX1/4 inhibitor GKT137831 (2–2(chlorophenyl)-4-[3(dimethylamino)phenyl]-5-methyl–1 H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione; #17164;
5μM in DMSO 15 min prior to IL-17A addition) was purchased from Cayman Chemical
(Ann Arbor, MI) and used as before ([9],[31]). DMSO was purchased from EMD
Biosciences (San Diego, CA). BioCoat™ Matrigel™ invasion chambers (# 354481) were
from BD/Discovery Labware (Bedford, MA). Pierce™ BCA Protein Assay Kit (#23227),
prestained protein molecular weight markers (#26612 and 26616) and SuperSignal® West
Femto Maximum Sensitivity Substrate (#34096) were purchased from Thermo Fisher
Scientific (Waltham, MA). Human kidney whole tissue lysate (adult whole normal;
#NB820–59231) was purchased from polyclonal rabbit anti-human MIP2/CXCL2
antibodies (NBP3–03233; 1:2500) Novus Biologicals (Centennial, CO). LDH (Lactate
Dehydrogenase) Cytotoxicity Assay Kit (#601170) was purchased from Cayman Chemical,
Ann Arbor, MI).

Author Manuscript
2.2.

Cell culture
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Human aortic SMC, purchased from LONZA *CC-2571), were grown in SmGM-2 basal
medium with SmGM™−2 SingleQuots™ supplements (LONZA, CC-4149) as previously
described ([5]). The cells were positive for αSMA (α smooth muscle actin) and SM-MHC
(smooth muscle myosin heavy chain), but not for VWF (Von Willebrand Factor) by RTqPCR using validated TaqMan® probes (data not shown). At 70–80% confluency, the
culture medium was replaced with basal medium containing 0.5% bovine serum albumin
(conditioning medium). After 48 h incubation, recombinant human IL-17A was added and
SMC were cultured for the indicated time periods. In our previous report, we tested IL-17A
at various concentrations, ranging from 1 to 50 ng/ml, and found that IL-17A at 25 ng/ml
induced maximal SMC proliferation ([5]). In studies examining the effect of IL-17A on
IL-1β and IL-18 mRNA expression, SMC were treated with rhIL-17A at 25 ng/ml for 2 h. In
studies examining the effect of IL-17A on IL-1β and IL-18 secretion, SMC were treated
with rhIL-17A at 25 ng/ml for 24 h. At the end of the experimental period, culture
supernatants were collected into slick tubes, snapfrozen, and stored at −80°C for subsequent
analysis by ELISA.
HK-2 (the human kidney-2) cells were purchased from ATCC® (CRL-2190 Manassas, VA).
HK-2 is an immortalized human proximal tubule cell line derived from a single cell isolated
from an adult male normal kidney. The cells were authenticated by ATCC®. The cells were
cultured in DMEM/F12 medium as previously described by us ([32]).
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Adenoviral vector expressing short hairpin RNA (shRNA) targeting human TRAF3IP2
(ad.TRAF3IP2 shRNA) was custom generated at Vector Biolabs (Malvern, PA). Ad.GFP
(#1060, Vector Biolabs) served as a non-targeting control. For adenoviral transduction, cells
were traduced with adenoviral vectors at moi10 for 1 h in basal medium and then switched
to complete medium for 24 h. Lentiviral vectors expressing shRNA targeting human NLRP3
(Product type: SHCLNV-NM_004895, TRC# TRCN0000432208; Target sequence:
CCGGGTGGATCTAGCCACGCTAATGCTCGAGCA
TTAGCGTGGCTAGATCCACTTTTTTG) and SGLT2 (SLC5A2; Product type: SHCLNVNM_003041, TRC# TRCN0000043603, Target sequence: CGGGCATATTTCCT
GCTGGTCATTCTCGAGAATGACCAGCAGGAAATATGCTTTTTG) were purchased
from Millipore-Sigma. Lentiviral shRNA targeting p65 subunit of NF-κB (#sc-29410-V)
and c-Jun subunit of AP-1 (#sc-29223-V) were purchased from Santa Cruz Biotechnology,
Inc., and have all been previously described ([11]). For lentiviral infection, SMC at 50–60%
confluency were infected with the indicated shRNA at a multiplicity of infection (moi) of
0.5 for 48 h in complete media. To increase transfection efficiency, cells were cotreated with
Polybrene® (5 μg/ml in water), a cationic polymer. Neither adenoviral or lentiviral shRNA
nor Polybrene® modulated SMC adherence, shape, or viability (trypan blue-dye exclusion;
data not shown).
2.4.

Superoxide and hydrogen peroxide production
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The generation of superoxide (O −•2) and hydrogen peroxide (H2O2) was quantified as
previously described ([33]). In brief, O −• 2generation was quantified using the lucigeninenhanced chemiluminescence assay as previously described ([6]). After subtracting
background luminescence, results are expressed as pmol superoxide/min/mg protein. Studies
were also performed after treating cells with the NOX2 inhibitor gp91 ds-tat (1 μM for 1 h).
A corresponding scrambled peptide (sgp91 ds-tat) served as a control. H2O2 production was
measured according to the manufacturer’s instructions using a commercially available kit in
the presence of horseradish peroxidase (0.1 unit/ml, Amplex Red: and 50 μM) according to
the manufacturer’s instruction and described in our previous report ([10]). Fluorescence was
recorded at 530 nm excitation and 590 nm emission wavelengths (CytoFluor II; Applied
Biosystems, Foster City, CA). Standard curves were generated using known concentrations
of H2O2. Studies were also performed after treatment with the Nox1/4 dual inhibitor
GKT137831. The results are expressed as μM H2O2 produced/106 cells.
2.5.

mRNA expression

Author Manuscript

DNA-free total RNA was prepared using the RNeasy Plus Micro Kit (#74034; Qiagen,
Germantown, MD). RNA quality was assessed by capillary electrophoresis using the Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). All RNA samples had RNA
integrity greater than 9.0 (scale = 1–10) as assigned by default parameters of the Expert
2100 Bioanalyzer software package (v2.02). mRNA expression was analyzed by RT-qPCR
using the following Applied Biosystems™ TaqMan™ probes: NLRP3 (Assay ID:
Hs00918082_m1), caspase-1 (Assay ID: Hs00354836_m1), IL1B (Assay ID:
Hs01555410_m1), IL18 (Assay ID: Hs01038788_m1), SGLT2 (Hs00894642_m1 [34] and
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Hs00894634_g1), MIP2 (CXCL2; Hs00601975_m1), and 18S (Hs99999901_s1). No
template controls were used for each assay, and samples processed without the reverse
transcriptase step served as a negative control. Each cDNA sample was run in triplicate.
Data were analyzed using the 2−ΔΔCt method. All data were normalized to corresponding
18S rRNA expression and presented as fold change from untreated control.
2.6.

Protein expression, secretion, and activity
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Preparation of whole cell homogenates, Western blotting, detection of the immunoreactive
bands by enhanced chemiluminescence (ECL Plus; GE Healthcare), and their quantification
by densitometry were all previously described ([5, 13, 32, 33]. Briefly, Cell lysates obtained
with Nonidet P-40 lysis buffer (0.5% Nonidet P-40, 10 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 3 mM p-amidinophenylmethanesulfonyl fluoride, 5 mg/ml aprotinin, 2 mM sodium
orthovanadate, 5 mM EDTA). Samples were separated by 10% SDS-PAGE, transferred to
polyvinylidene difluoride membrane, and probed with primary antibodies diluted in 2%
nonfat dry milk in Tris-buffered saline containing 0.05% Tween 20 (TTBS) overnight at 4
°C. The blots were rinsed in TTBS for 30 min and then incubated in species-specific HRPconjugated secondary antibodies in 5% milk in TTBS for 1 h and developed using the
SuperSignal® West Femto Maximum Sensitivity chemiluminescent substrate. The following
primary antibodies at indicated dilutions/concentrations were used: TRAF3IP2 (1:400;
NB100–56740, Novus Biologicals, Centennial, CO), ASK1 (1:1000; #3762, Cell Signaling
Technology/CST, Danvers, MA), Tubulin (1:1000; #2144, CST), p-p65 (1:1000; #3031,
CST), p65 (1:1000; #3033, CST), cleaved Caspase-1 (1:1000; #4199, CST), NLRP3 (2.5
μg/ml; #NBP2–12446, NOVUS Biologicals), and SGLT2 (1:100; #sc-393350; Santa Cruz
Biotechnology, Inc., Dallas, TX). Secreted IL-1β IL-18 levels in equal amounts of culture
supernatants were quantified by ELISA. Secreted cytokine levels were also analyzed by
Western blotting using equal amounts of culture supernatants after concentrating with
Amicon Ultra-2 Centrifugal Filter Units. Caspase-1 activity was analyzed according to the
manufacturer’s instructions using the Caspase-1/ICE Colorimetric Assay Kit.
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2.7.

Cell proliferation
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SMC proliferation was analyzed as described previously ([5, 9, 33]. In brief, SMC were
seeded at a concentration of 1×103 cells/well in 200 μl of complete medium in 96-well clear
bottom, black-sided flat-bottom plates (VWR Scientific Products, West Chester, PA). After
24 h incubation, the complete medium was replaced with medium containing 0.5% BSA and
no fetal bovine serum (conditioning medium) and incubated for an additional 48 h
(quiescence). The quiescent cells were then incubated with IL-17A for 48 h. Afterward the
medium was removed and plates were frozen at −80°C for 2 h before assay. Plates were then
thawed, stained with CyQUANT GR dye according to manufacturer’s protocol (Molecular
Probes, Eugene, OR), and read on a FLX800 microplate fluorescence reader (Bio- Tek
Instruments, Winooski, VT) using 485/20 excitation and 528/20 emission filters, and
analyzed using KC4 software (Bio- Tek Instruments).
2.8.

Cell migration
SMC migration was quantified as described previously using BioCoat™ Matrigel™ invasion
chambers and 8.0-μm pore polyethylene terephthalate membranes with a thin layer of
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Matrigel™ basement membrane matrix ([5, 8, 31, 33]. Cultured SMC were trypsinized and
suspended in medium containing 0.5% bovine serum albumin, and 1 ml containing 2.0 × 105
cells/ml was layered on the coated insert filters. Cells were stimulated with IL-17A (25 ng/
ml). The lower chamber contained IL-17A at the same concentration. Plates were incubated
at 37 °C for 18 h. Membranes were washed with phosphate-buffered saline, and noninvading cells on the upper surface were removed using cotton swabs. Cells migrating to the
lower surface of the membrane were determined at A540 nm using MTT assay.
2.9.

Cell vitality

Author Manuscript

To determine the potential effects of IL-17A, phramacologiocal inhibitors, neutralizing
antibodies and shRNA on cell damage and death, we analyzed LDH (lactate dehydrogenase)
activity at 8 h in culture supernatants according to the manufacturer’s instructions using the
LDH Cytotoxicity Assay Kit. In brief, the assay analyzes the integrity of cell membrane as
damage to the cell membrane permits the leakage of LDH into culture supernatants. This is a
two-step assay; in the first step, LDH catalyzes the reduction of NAD+ to NADH and H+ by
oxidation of lactate to pyruvate, and in the second step, diaphorase uses the newly formed
NADH and H+ to catalyze the reduction of a tetrazolium salt (INT) to highly colored
formazan which absorbs strongly at 490–520 nm. Hydrogen peroxide (100 μM for 24 h)
served as a positive control. Each LDH activity value was compared with that of LDH
released into culture supernatant after incubation with 0.1% Triton X-100, a nonionic
surfactant that permeabilizes cell membranes (total LDH release) and expressed as a
percentage of total release.
2.10.

Statistical analysis

Author Manuscript

All data are expressed as mean ± SE. Statistical significance was determined by one-way
analysis of variance followed by Tukey’s post hoc test (GraphPad Prism software, San
Diego, CA). Differences are considered significant if the P value is <0.05. Further, though a
representative Western blot is shown in the main figures, changes in target protein
expression from three to four independent experiments were semi-quantified by
densitometry, and presented at the bottom or side of respective panels as fold changes over
control, which was set at a value of 1. The numbers at the bottom of each panel in figures
denote lane numbers.

3.

Results

3.1. IL-17A stimulates human aortic smooth muscle cell (SMC) migration and proliferation
via TRAF3IP2-dependent ROS generation

Author Manuscript

Exposure to IL-17A, as detailed in Fig. 1A, at 25 ng/ml, stimulated proliferation of SMC
(Fig. 1B) as reported by us previously ([5]). PDGF-BB (10 ng/ml) served as a positive
control, and significantly increased SMC proliferation (Fig. 1B). TRAF3IP2, a critical
downstream signaling intermediate of IL-17A, and its knockdown by an adenoviral vector
encoding a short hairpin RNA directed against TRAF3IP2 (Ad.TRAF3IP2 shRNA) led to a
marked inhibition in IL-17A-mediated SMC proliferation (Fig. 1C) and migration (Fig. 1D).
Importantly, these anti-mitogenic and anti-migratory effects of silencing TRAF3IP2 in
IL-17A treated cells, did not result from reduced cell viability, as evidenced by the low
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levels of LDH activity in equal amounts of culture supernatants (Fig. 1E). Additionally,
adenoviral transduction of GFP shRNA modulated neither proliferation (Fig. 1C), migration
(Fig. 1D) nor cell viability (Fig. 1E). However, hydrogen peroxide (100μM), used as a
positive control, induced cell death as evidenced by a marked increase in LDH activity in
culture supernatants (Fig. 1E).

Author Manuscript

Since TRAF3IP2 is an oxidative stress-responsive cytoplasmic adapter molecule ([32], [8],
[7], we next investigated whether IL-17A induces oxidative stress. We quantified superoxide
and hydrogen peroxide as markers of oxidative stress. Indeed, IL-17A induced O2−•
generation (Fig. 1F), an effect markedly inhibited by the broad-spectrum antioxidant NAC
and the NOX2 inhibitor gp91 ds-tat, but not by the scramble peptide, sgp91 ds-tat. Exposure
to IL-17A also stimulated hydrogen peroxide production (Fig. 1G), an effect inhibited by
NAC and the NOX1/4 dual inhibitor GKT137831. Importantly, NAC, gp91 ds-tat and
GKT137831 each attenuated IL-17-induced upregulation in TRAF3IP2 expression (Fig.
1H). Recombinant IL-17A contained trace amounts of endotoxin. Therefore, to exclude the
possibility that the mitogenic and migratory effects of IL-17A, and TRAF3IP2 induction, are
mediated by these trace amounts of endotoxin (<0.10 EU/1μg of recombinant protein), we
next exposed SMC to recombinant human IL-17A preincubated with the endotoxin inhibitor
polymyxin B. These experiments revealed that exposure to IL-17A pretreated with
polymyxin B failed to affect SMC proliferation and migration (Fig. 1I, 1J), suggesting that
the low levels of contaminating endotoxin in the recombinant protein samples had no
significant effect on IL-17A’s mitogenic and migratory effects. Taken together, these results
indicate that the proinflammatory cytokine IL-17A exerts mitogenic and migratory effects in
SMC via oxidative stress-responsive TRAF3IP2 expression (Fig. 1).
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3.2.

IL-17A induces SMC proliferation and migration via IL-1β and IL-18

Author Manuscript

Both IL-1β and IL-18 are transcriptionally regulated proinflammatory cytokines and their
increased expression plays a pathological role in vascular proliferative diseases, including
atherosclerosis ([22] [23],[24]). Results show that SMC exposure to IL-17A, as detailed in
Fig. 2A, upregulated IL-1β and IL-18 mRNA expression by 6- to 8-fold (Fig. 2B, 2C).
Consistent with increased mRNA expression, IL-17A also enhanced their protein
expression, as shown in insets in Fig. 2B and 2C. Since both cytokines are secreted proteins,
we next measured their secreted levels in equal amounts of culture supernatants by ELISA.
The data show that IL-17A significantly enhanced their secretion (Fig. 2D and 2E). In
addition to ELISA, we also measured secreted cytokine levels in concentrated culture
supernatants by Western blotting. The results show that the majority of cytokines detected in
culture supernatants is the mature form, with trace to undetectable amounts of respective
proforms (Fig. 2D and 2E). Importantly, silencing TRAF3IP2 inhibited their mRNA and
protein expression, and secretion (Fig. 2B–2E). Furthermore, pre-incubation with IL-1β
neutralizing antibodies (experimental design in Fig. 2F) attenuated IL-17A-induced SMC
proliferation (Fig. 2G) and migration (Fig. 2H). Similarly, pretreatment with IL-18
neutralizing antibodies or its naturally occurring endogenous inhibitor, IL-18BP, as shown in
Fig. 2F, attenuated IL-17A’s mitogenic and migratory effects (Fig. 2G and 2H). However,
the inhibitory effects of these neutralizing antibodies and IL-18-BP are not as a consequence
of reduced cell viability, as evidenced by the low levels of LDH activity in equal amounts of
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culture supernatants. Together, these results indicate that IL-17A-induced SMC proliferation
and migration are mediated, in part, via TRAF3IP2-dependent IL-1β and IL-18 (Fig. 2).
3.3.

IL-17A induces NLRP3 expression via NF-κB, AP-1 and p38MAPK

Author Manuscript

We have demonstrated that IL-17A induces SMC proliferation and migration, in part, via
IL-1β and IL-18 (Fig. 2). Both IL-1β and IL-18 are synthesized as precursors and released
as biologically active cytokines by the cytosolic NLRP3 inflammasome ([27, 35, 36]).
Therefore, we next investigated whether IL-17A induces NLRP3 expression as well as the
signaling intermediates that play a role in its induction. The data show that, exposure to
IL-17A, as shown in Fig. 3A, increased NLRP3 expression (Fig. 3B), an effect significantly
inhibited by TRAF3IP2 knockdown. We have previously demonstrated that NF-κB, AP-1
and p38MAPK are downstream targets of TRAF3IP2 ([11], [9]). Therefore, we next
investigated whether IL-17A-mediated NLRP3 expression is dependent on these signaling
intermediates. We targeted the p65 subunit of NF-κB and the c-jun subunit of AP-1 by
lentiviral transduction of validated shRNA, and p38MAPK by SB239063 or SB202190, two
different, but highly specific, pharmacological inhibitors. Silencing p65 and c-Jun markedly
attenuated IL-17A-induced NLRP3 expression (Fig. 3C). Further, pharmacological
inhibition of p38 MAPK significantly inhibited IL-17A-induced NLRP3 expression (Fig.
3D). However, knockdown of p65 or c-Jun, or pharmacological inhibition of p38 MAPK did
not increase LDH activity in culture supernatants (Fig. 3E). Together, these results indicate
that IL-17A induces NLRP3 expression in SMC via NF-κB, AP-1 and p38 MAPK (Fig. 3).
3.4.

IL-17A induces caspase-1 expression and activation via NLRP3

Author Manuscript

Both IL-1β and IL-18 are synthesized as inactive precursors and cleaved by caspase-1 to
become biologically active ([25, 36]). In general, caspase-1, also known as IL-1β converting
enzyme (ICE), is activated via an autocatalytic pathway due to its proximity and recruitment
to the inflammasome ([35]). Since IL-17A upregulated NLRP3 expression and stimulated
the expression both IL-1β and IL-18 (Fig. 2 and 3), we next investigated whether IL-17A
induces caspase-1 activation via NLRP3. NLRP3 expression was targeted by MCC950 and
dapansutrile. Our results demonstrate that pretreatment with the NLRP3 inhibitors MCC950
and dapansutrile prior to IL-17A addition (experimental design is shown in Fig. 4A)
markedly inhibited IL-17A-induced caspace-1 activation, as evidenced by a significant
decrease in cleaved caspase-1 levels (Fig. 4B). Using a colorimetric assay, we further
confirmed inhibition of caspase-1 activity by the NLRP3 inhibitors (Fig. 4C). However,
neither MCC950 nor dapansutrile modulated MIP2 mRNA and protein levels (Fig. 4D) or
LDH activity in culture supernatants (Fig. 4E), suggesting that IL-17A-induced IL-1β and
IL-18, but not MIP2 expression, is NLRP3-dependent. Together, these results indicate that
IL-17A induces caspase-1 activation via NLRP3 (Fig. 4).
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3.5.

IL-17A induces SMC proliferation and migration via NLRP3 and caspase-1
Since NLRP3 inflammasome serves as a platform for caspase-1 recruitment and activation
that cleaves pro-IL-1β and pro-IL-18 to their respective mature and functionally active forms
([36], [37]), we next investigated whether IL-17A induces cytokine expression, and SMC
proliferation and migration via NLRP3 and caspase-1. Caspase-1 was targeted by a cell
permeable irreversible pan-caspase inhibitor Z-WEHD-FMK and a caspase-1-specific
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inhibitor Z-VAD-FMK ([38]). Consistent with the results shown in Fig. 2, exposure to
IL-17A, as described in Fig. 5A, significantly increased IL-1β (Fig. 5B) and IL-18 (Fig. 5C)
secretion quantified by ELISA and Western blotting, an effect markedly inhibited by
pharmacological inhibition of NLRP3, as well as NLRP3 knockdown. Further, pre-treatment
with Z-WEHD-FMK and Z-VAD-FMK, at indicated concentrations, each inhibited IL-17Ainduced IL-1β (Fig. 5B) and IL-18 (Fig. 5C) secretion. Importantly, targeting NLRP3 and
caspase-1 each attenuated IL-17A-induced SMC proliferation (Fig. 5D) and migration (Fig.
5E), without increasing LDH activity (Fig. 5F). These results indicate that IL-17A induces
proinflammatory IL-1β and IL-18 expression, and SMC proliferation and migration, in part,
via NLRP3-dependent caspase-1 activation (Fig. 5).
3.6. EMPA inhibits IL-17A-induced oxidative stress and TRAF3IP2 expression without
inducing cell death

Author Manuscript
Author Manuscript

Because SGLT2 inhibitors, including EMPA, exert pleiotropic antioxidant and antiinflammatory effects independent of their blood sugar lowering properties, we next
investigated whether EMPA modulates IL-17A-induced oxidative stress and TRAF3IP2
expression. At first, we investigated whether SMC express SGLT2 and whether IL-17A
regulates its expression. Confirming an earlier report ([21]), results show that SMC
(experimental design in Fig. 6A) express SGLT2 mRNA and protein at basal conditions
(Fig. 6B and 6C), albeit at a lower level than in whole human kidney homogenates and HK-2
cell lysates (~1/10th of that seen in whole kidney and ~1/4th seen in HK-2 cell homogenates)
(Fig. 6B). Moreover, its expression was not modulated when culture media was switched
from complete medium to conditioning medium. However, when exposed to IL-17A, SGLT2
expression increased both at mRNA and protein levels (Fig. 6C and 6D) in a time dependent
manner, with significantly increased protein levels detected after 30 min (Fig. 6D). Its levels
remained high even at 24h compared to its basal expression. Further, pre-treatment with
EMPA, as described in Fig. 6E, inhibited IL-17A-induced superoxide generation in a dosedependent manner, with a marked, but similar levels of inhibition seen at both 1 and 5μM
concentrations (Fig. 6F). Therefore, in all subsequent experiments, EMPA was used at a
clinically relevant 1 μM concentration. At this concentration, EMPA also inhibited IL-17Ainduced hydrogen peroxide production (Fig. 6G) and TRAF3IP2 induction (Fig. 6H),
without increasing LDH activity in culture supernatants (Fig. 6I), indicating that the
observed inhibitory effects of EMPA on oxidative stress and TRAF3IP2 expression are not
due to reduced cell viability. Together, these results indicate that SMC express SGLT2 at a
low basal level, and increased following exposure to IL-17A. Moreover, EMPA inhibits
IL-17A-induced oxidative stress and TRAF3IP2 expression without modulating cell viability
(Fig. 6).
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3.7.

EMPA inhibits IL-17A-induced SMC proliferation and migration
Since IL-17A induced SMC proliferation and migration in part via NLRP3/caspase-1dependent IL-1β and IL-18 expression (Fig. 2 and Fig. 4), we next investigated whether
EMPA exerts anti-mitogenic and anti-migratory effects by targeting NLRP3, caspase-1, and
cytokine expression. Consistent with results in Fig. 3B, exposure to IL-17A, as described in
Fig. 7A, upregulated NLRP3 expression (Fig. 7B), and pretreatment with EMPA suppressed
this effect in a dose-dependent manner (Fig. 7B), with maximal inhibition seen at 1 and 5μM
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concentrations, and without inducing cell death at either concentration as evidence by no
significant change in LDH activity (Fig. 7C). At 1μM concentration, EMPA also suppressed
caspase-1 activation, as evidenced by a marked reduction in cleaved caspase-1 levels (Fig.
7D) and activity (Fig. 7E). EMPA also inhibited IL-1β (Fig. 7F) and IL-18 (Fig. 7G) protein
secretion. Importantly, EMPA inhibited IL-17A-induced SMC proliferation (Fig. 7H) and
migration (Fig. 7I). Together, these results indicate that EMPA suppresses IL-7A-induced
SMC proliferation and migration by targeting NLRP3/caspase-1/IL-1β/IL-18 axis (Fig. 7).
3.8. Silencing SGLT2 attenuates the inhibitory effects of EMPA on IL-17A-induced
cytokine secretion and SMC proliferation and migration.
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Since EMPA exerted anti-inflammatory, antimotogenic and anti-migratory effects in SMC,
and as EMPA signals mainly via SGLT2, we next investigated whether silencing SGLT2
reverses the protective effects of EMPA on IL-17A-induced cytokine secretion and SMC
proliferation and migration. Therefore, we silenced SGLT2 using lentiviral transduction of
SGLT2-specific shRNA as described in Fig. 8A. Knockdown of SGLT2 was confirmed by
Western blotting (Fig. 8B), with MyD988 serving as an off-target. The SGLT2-silenced
SMC were then exposed to IL-17A. The secreted IL-1β and IL-18 levels were quantified by
ELISA. We also estimated the secreted cytokine levels by Western blotting after
concentrating the culture supernatants. The results in Fig. 8C and 8D show that silencing
SGLT2 partially blunted the inhibitory effects of EMPA on secreted cytokine levels.
Silencing SGLT2 also partially reversed the inhibitory effects of EMPA on IL-17A-induced
SMC proliferation (Fig. 8E) and migration (Fig. 8F). Together, these results indicate that
EMPA exerts its inhibitory effects on IL-17A-induced cytokine secretion, and SMC
proliferation and migration in part via SGLT2 (Fig. 8).

Author Manuscript

4.

Discussion

Author Manuscript

Persistent inflammation and oxidative stress contribute to the development and progression
of vascular proliferative diseases, with SMC proliferation and migration playing a critical
role in their pathogenesis. In this mechanistic in vitro study, we show that human aortic
smooth muscle cells (SMC) express SGLT2 mRNA and protein, and treatment with EMPA,
a potent and selective SGLT2 inhibitor used to treat hyperglycemia in diabetic patients ([39–
42], attenuates IL-17A/TRAF3IP2-mediated oxidative stress, NLRP3 expression, caspase-1
activation, IL-1β and IL-18 secretion, and SMC migration and proliferation. Interestingly,
EMPA exerted these antioxidant, anti-inflammatory, anti-migratory and anti-mitogenic
effects under normal glucose conditions and without inducing cell death (Fig. 9). These
results support the therapeutic potential of EMPA in the treatment of vascular proliferative
diseases.
Chronic oxidative stress contributes to SMC proliferation and migration [43–45]. Here we
show that, EMPA inhibits IL-17A-mediated oxidative stress at a clinically relevant dose, as
indicated by a significant reduction in superoxide and hydrogen peroxide production, and
TRAF3IP2 induction. These results support earlier reports that demonstrated that the SGLT2
inhibitors inhibit oxidative stress both in vitro and in vivo ([46–49], via inhibition of prooxidant enzyme systems or potentiation of antioxidant defenses. NADPH oxidases (NOX)
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play a major role in ROS generation and oxidative stress ([50, 51]), and the initial generation
of ROS by NOXes amplifies oxidative stress by further enhancing ROS generation by other
pro-oxidant systems [52]. Here we show that EMPA inhibits IL-17A-induced NOX2dependent superoxide generation in SMC. Similar results were reported previously, where
EMPA improved chronic hyperglycemia-induced vascular dysfunction by targeting NOX2
activity ([53]), further confirming the antioxidant effects of EMPA. Here we report that, in
addition to inhibition of NOX2, EMPA also inhibits IL-17A-mediated NOX4-dependent
hydrogen peroxide production in SMC. This confirms our earlier results, where EMPA
inhibited hyperglycemia-induced NOX4-mediated hydrogen peroxide production in a human
renal proximal tubular epithelial cell line ([32]). Though we focused on NOX2- and NOX4mediated oxidative stress in the current investigation, SGLT2 inhibitors have also been
shown to inhibit ROS generation and oxidative stress by targeting the polyol pathway,
mitochondrial dysfunction, iNOS induction, NO generation, and peroxynitrite formation in
diverse cell types (reviewed in [54]).
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In fact, the outcomes of the EMPA-REG (Empagliflozin Multicenter, International,
Randomized, Parallel Group, Double Blind Cardiovascular Safety Study) and CANVAS
trials have suggested that suppression of oxidative stress by SGLT2 inhibitors is one of the
underlying mechanisms that contributed to reduced cardiovascular events, emphasizing the
pleiotropic antioxidant potential of EMPA [55, 56]. In addition to inhibition of oxidative
stress, we also report for the first time that EMPA inhibits TRAF3IP2 expression in SMC.
These results are consistent with our previous report demonstrating inhibition of TRAF3IP2
in high glucose-treated human proximal tubule epithelial cells ([32]). TRAF3IP2 is a
signaling intermediate critical in IL-17A signaling. TRAF3IP2 physically associates with
IL-17 receptors through SEFIR (Similar Expression to Fibroblast growth factor genes and
Interleukin-17 Receptor)-SEFIR interaction and activates multiple downstream oxidative
stress-responsive proinflammatory pathways [57]. We and others have demonstrated
TRAF3IP2-dependent activation of proinflammatory transcription factors and stressactivated kinases, including NF-κB, AP-1, and p38 MAPK, in cells of vascular and nonvascular origin. Of note, NF-κB, AP-1, and p38 MAPK have all been shown to regulate
NOX2 and NOX4 expression and oxidant stress in various cell types. Moreover, SMCspecific inhibition of NF-κB by overexpressing a truncated version of IκB attenuated
phenotypic switching of SMC in vitro and neointima formation in vivo following injury
([58]). Interestingly, TRAF3IP2 is an oxidative stress-responsive adapter molecule,
indicating that it acts both upstream and downstream of oxidative stress. In fact, the
promoter region of TRAF3IP2 contains binding sites for several oxidative stress-responsive
cis-regulatory elements, including AP-1, IRF-1, and c/EBP. High glucose-induced
endothelial dysfunction is mediated via AP-1-, IRF-1-, c/EBP-1-dependent TRAF3IP2
expression as we reported previously [11]. The results from this and other studies indicate
that EMPA exerts pleiotropic antioxidant and anti-inflammatory effects in vascular and other
cell types under both high and normal glucose conditions.
In general, oxidative stress and inflammation co-exist and their persistent induction
contributes to the pathogenesis of various chronic inflammatory diseases, including vascular
proliferative diseases. Of note, inflammatory mediators also contribute to oxidative stress;
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they increase free radical generation, including NOX2- and NOX4-dependent superoxide
and hydrogen peroxide production, respectively [59, 60]. Here we show that EMPA inhibits
the proinflammatory and pro-atherogenic cytokines IL-1β and IL-18 in SMC by inhibiting
NLRP3 expression. These results support a prior report demonstrating EMPA-mediated
inhibition of NLRP3 inflammasome activation in liver and kidney, but not heart, in a murine
model of diet (high fat/high sugar)-induced obesity and insulin resistance [26]. Herein, we
have not specifically investigated the molecular mechanisms underlying EMPA-mediated
downregulation of NLRP3 expression and activation. As such, we hypothesize that reduced
oxidative stress and inhibition of NF-κB and AP-1 activation contributed to EMPA-mediated
NLRP3 downregulation, given that the NLRP3 promoter region contains multiple NF-κBbinding sites [61] and putative binding sites for AP-1, Sp1, cMyb, and c-ETS [62].
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Consequent to inhibition of NLRP3 expression, EMPA attenuated IL-17A-mediated IL-1β
and IL-18 expression. Both cytokines are induced following vascular injury and play a role
in intimal hyperplasia, either alone or in combination with growth factors [63, 64]. We
previously reported that IL-18 enhances IL-18R/NOX1 physical association, TRAF3IP2
induction, and SMC migration [65], indicating that oxidative stress and TRAF3IP2 each
contribute to the promigratory effects of IL-18. We further demonstrated that targeting NFκB and AP-1 inhibit IL-18-induced MMP-9 expression and SMC migration [66]. Of note,
Il18 is also an NF-κB and AP-1-responsive gene, indicating that induction of TRAF3IP2,
activation of NF-κB and AP-1, and upregulation of inflammatory cytokines collectively
perpetuate inflammation and oxidative stress in vasculature, ultimately resulting in vascular
proliferative diseases, characterized by SMC proliferation and migration.
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IL-17A stimulated IL-1β secretion in an NLRP3-dependent manner, and like IL-18, Il1b is
also an AP-1 and NF-κB responsive gene. IL-1β has been previously shown to play a role in
porcine artery response to injury [67] and carotid artery ligation-induced neointima
formation [68]. Moreover, high levels of IL-1β were detected in human atherosclerotic
coronary arteries [69]. IL-1β is also shown to promote SMC migration [70], and promote
SMC proliferation by enhancing oxidative stress and the induction of multiple inflammatory
mediators in SMC [71]. Consistent with published reports, our data show that IL-17A
induced SMC migration and proliferation, in part, via IL-1β. Importantly, we show that
EMPA inhibits inducible IL-1β expression and secretion. Since EMPA also inhibits the
expression of multiple inflammatory mediators that are known to contribute to vascular
proliferative diseases, such as TNF-α, IL-6, and MCP-1, one can argue that EMPA has the
potential to inhibit the progression of vascular proliferative diseases by targeting oxidative
stress-responsive pro-inflammatory mediators, including IL-18 and IL-1β in SMC.
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In the current in vitro investigation, we have demonstrated that IL-17A-induced SMC
proliferation and migration are mediated in part via NLRP3/Caspase-1-dependent IL-1β and
IL-18 expression. However, in vivo, monocyte/macrophage activation is evident in vascular
proliferative diseases, and these leukocytic cell types are generally regarded as more
efficient sources of mature IL-1β and IL-18 as compared to SMC. For example, in human
atherectomy samples, IL-18 expression was predominantly seen in macrophages and
correlated with plaque instability [72]. In another study, macrophages in atheroma were
shown to express the mature form of IL-18, while SMC in the lesions expressed its receptors
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[73], indicative of paracrine effects of macrophage-secreted mature IL-18 on IL-18R
expressing SMC. Similarly, macrophages are shown to be the predominant source of IL-1β
in vascular proliferative diseases. For example, macrophages isolated from subjects with
restenosis following angioplasty expressed high levels of IL-1β [74]. Increased IL-1β has
also been demonstrated in human atherosclerotic lesions [69], localized predominantly to
macrophages and endothelial cells. Its increased circulating levels also serve as a risk factor
for coronary artery disease in hypertensive subjects [75]. Together, data from the current
investigation and published reports indicate that IL-1β and IL-18 expressed and secreted by
multiple cell types contribute to vascular proliferative diseases.
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Here we have demonstrated that EMPA exerts its beneficial effects in SMC in part via
SGLT2, as silencing SGLT2 did not abrogate its protective effects, indicating that some of its
protective effects are mediated in SGLT2-independent manner. In fact, in many studies
where SGLT2 inhibitors have shown protective effects, whether their beneficial effects are
mediated via SGLT2 are not investigated. For example, the SGLT2 inhibitors EMPA and
dapagliflozin are shown to inhibit stearic acid-induced oxidative stress and inflammatory
cytokine expression in myeloid angiogenic cells and platelets [76]. Interestingly, neither cell
type expressed SGLT2 mRNA or protein. However, both cell types expressed Sodium/
Hydrogen Exchanger 1 (NHE-1), a member of the solute carrier family 9, that plays a role in
pH homeostasis and cell migration [77]. Amiloride, a broad spectrum NHE inhibitor and
Cariporide, an NHE-1-specific inhibitor, each suppressed stearic acid-induced inflammatory
markers [76], indicating that EMPA and dapagliflozin rather functioned through inhibition
of NHE, but not SGLT2, in those cell types. Further, using in silico analysis of SGLT2
inhibitor binding to a homology model of NHE, those authors also reported that EMPA and
other SGLT2 inhibitors could efficiently bind the Na+-binding pocket of NHE. Of note,
vascular SMC express NHE-1, but not NHE-2, NHE-3 or NHE-4 [78], and inhibition of
NHE-1 by amiloride or dimethyl amiloride blunts lysophosphatidic acid-induced vascular
SMC proliferation [79]. Therefore, it appears that EMPA and other SGLT2 inhibitors act via
SGLT2 and/or NHE in cell types other than renal proximal tubule epithelial cells.
Interestingly, however, dapagliflozin has been shown to inhibit NHE-1 expression in LPStreated cultured cardiac fibroblasts [80], suggesting cell type-specific effects of SGLT2
inhibitors on NHE-1 expression and/or activation.
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Our study has some limitations: (i) This is an in vitro mechanistic study using primary
human aortic SMC and this model may not recapitulate all the complex pathophysiological
process regulated in a diseased vessel. However, it can also be considered a strength, as we
have investigated the effects of IL-17A and EMPA in a pure population of SMC, ruling out
the potential paracrine effects and cell-cell interactions with other vascular cells on SMC
proliferation and migration. (ii) Confirming an earlier report [21], we have demonstrated the
expression of SGLT2 by RT-qPCR and Western blotting in SMC, but at a level lower than in
whole kidney and a proximal tubule epithelial cell line. Importantly, we have also
demonstrated that IL-17A induces its expression. Interestingly, the inhibitory effects of
EMPA were partially attenuated when SGLT2 was silenced. Since SMC also express NHE-1
[78], an off-target of SGLT2 inhibitors, it is plausible that EMPA might function via both
SGLT2 and NHE-1 in SMC (Fig. 9). Our future studies will determine whether amiloride
potentiates the inhibitory effects of EMPA on IL-17A-induced NLRP3 inflammasome
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activation, inflammatory cytokine expression, and SMC proliferation and migration. Another
limitation of the study is that (iii) though we have demonstrated for the first time that
IL-17A induces SGLT2 expression at both mRNA and protein levels, we have not
investigated whether this increased expression is due to enhanced transcription or mRNA
stability or both. Of note, administration of LPS, a known inducer of pro-inflammatory
mediators, has been shown to suppress SGLT2 expression in mouse kidneys [81]. In that
study, injection of cytokines, such as IL-1, IL-6, or TNF-α, also suppressed SGLT2
expression in kidneys [81]. In contrast, IL-6 and TNF-α were shown to induce SGLT2
expression in cultured porcine kidney epithelial cells under normal glucose conditions, but in
a delayed manner [82]. Moreover, insulin has been shown to induce SGLT2 expression via
oxidative stress in proximal tubule epithelial cells [82]. These conflicting results suggest that
the regulation of SGLT2 is complex, and the signaling pathways underlying its expression
and regulation need a thorough investigation. While we focused mainly on EMPA-mediated
inhibition of IL-17A-induced oxidative stress, reduced oxidative stress also results from
enhanced antioxidant defenses. Therefore, in future studies, (iv) we will investigate whether
EMPA, which inhibited NOX2- and NOX4-mediated superoxide and hydrogen peroxide
production, also blunts IL-17A-induced oxidative stress by enhancing or restoring the
expression and activity of antioxidant enzymes, such as catalase, glutathione peroxide, MnSOD, and Cu/ZN SOD, that are shown to be enhanced in diabetic mice treated with a
SGLT2 inhibitor [47].
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In summary, our results demonstrate that EMPA exerts pleiotropic effects, and inhibits SMC
migration and proliferation by targeting IL-17A-mediated oxidative stress, NLRP3
expression, and inflammation under normal glucose conditions and without inducing cell
death. These results suggest the therapeutic potential of EMPA in vascular proliferative
diseases.
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Act1

Nuclear Factor NF-Kappa-B Activator 1

ApoE

Apolipoprotein E

ASK1

Apoptosis Signal Regulated Kinase 1

CIKS

Connection to IKK and SAPK/JNK

CXCL2

C-X-C Motif Chemokine Ligand 2

DMSO

Dimethyl Sulfoxide

EMPA

Empagliflozin
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IL, IKK

IκB Kinase; Interleukin

LDH

Lactate Dehydrogenase

MIP

Macrophage Inflammatory Protein

MMP

matrix metallopeptidase

moi

multiplicity of infection

NHE

Na+/H+ Exchanger

NLRP3

Nucleotide-binding domain and Leucine-rich repeat containing
Family Pyrin Domain Containing 3

PDGF

Platelet Derived Growth Factor

ROS

Reactive oxygen species

SAPK

Stress-Activated Protein Kinase

SEFIR

similar expression to fibroblast growth factor genes) and IL-17R

SGLT2

Sodium/Glucose Cotransporter 2

SLC5A2

Solute Carrier Family 5 Member 2

αSMA

alpha smooth muscle actin

SMC

Human aortic smooth muscle cells

SM-MHC

Smooth Muscle Myosin Heavy Chain

TRAF

Tumor Necrosis Factor Receptor Associated Factor

TRAF3IP2

TRAF3 Interacting Protein 2

VWF

Von Willebrand Factor
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Highlights
1.

Human aortic smooth muscle cells (SMC) express SGLT2

2.

The SGLT2 inhibitor empagliflozin inhibits IL-17-induced oxidative stress in
SMC

3.

Empagliflozin inhibits NLRP3 expression, caspase-1 activation, and
inflammatory cytokine expression

4.

Empagliflozin inhibits IL-17A-induced SMC proliferation and migration.

5.

Empagliflozin has therapeutic potential in vascular proliferative diseases.
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Figure 1. IL-17A induces human aortic smooth muscle cell (SMC) proliferation and migration.
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(a) Experimental design. (b) IL-17A at 25 ng/ml stimulated SMC proliferation, while
recombinant human PDGF-BB served as a positive control. (c) Adenoviral shRNA-mediated
TRAF3IP2 knockdown markedly attenuates IL-17A-induces SMC proliferation. Adenoviral
transduction of GFP shRNA failed to modulate IL-17A’s pro-mitogenic effects. The inset on
the left confirms downregulation in TRAF3IP2 expression by TRAF3IP2-specific shRNA,
but not by the non-specific GFP shRNA at a similar multiplicity of infection. (d) TRAF3IP2
silencing leads to inhibition of IL-17A-mediated SMC migration. Boyden chamber assay
demonstrating inhibition of IL-17A-mediated SMC migration by adenoviral-mediated
TRAF3IP2 silencing. (e) A quantitative colorimetric assay to determine LDH activity in
equal amounts of culture supernatants to determine cell death. Hydrogen peroxide (100 μM)
served as a positive control. (f,g) IL-17A treatment leads to increased superoxide (O2 −•; f)
and hydrogen peroxide (H2O2; g) production in SMC via NOX2 and NOX4. NAC (5mM in
water for 30 min) served as a broad-spectrum antioxidant. NOX2 was targeted by gp91 dstat (1μM for 1 h). NOX4 was targeted by GKT137831 (5μM in DMSO 15 min). (h)
Importantly, targeting NOX2 and NOX4 attenuated IL-17A-induced TRAF3IP2 expression.
(i,j) Polymyxin B pretreatment of IL-17A had no modulatory effect on IL-17A-induced
proliferation (i) or migration (j). Quiescent SMC were exposed to IL-17A that has been
preincubated with polymyxin B for 1h. SMC proliferation and migration were analyzed as in
b and d. Data represent mean ±SE of 8 (proliferation) or 6 (migration) independent
experiments. The data presented in (e) is a representative of three independent experiments.
*P<at least 0.01 versus untreated; †P<0.05 versus IL-17A.
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Figure 2. IL-17A induces aortic SMC proliferation and migration via IL-1β and IL-18.
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(a) Experimental design for IL-17A-induced cytokine expression and secretion. (b-e, IL-17A
induces IL-1β and IL-18 expression and secretion by SMC. Quiescent SMC treated with
IL-17A were analyzed for IL-1β and IL-18 mRNA expression by RT-qPCR and protein
levels (b,c) by Western blotting at 2 h, and secreted levels by ELISA (d,e) at 24h. In
addition, IL-1b and IL-18 levels were analyzed by Western blotting after concentrating
culture supernatants (d,e, insets). In a subset of experiments, TRAF3IP2 was silenced by
adenoviral transduction of a validated shRNA as in Fig. 1B, prior to IL-17A treatment. In the
knockdown studies, GFP served as a non-targeting control. (f) Experimental design for
IL-1β and IL-18 neutralization. (g,h) Anti-IL-1β and anti-IL-18 neutralizing antibodies blunt
IL-17A-induced SMC proliferation (g) and migration (h). In addition to neutralizing
antibodies, IL-18 expression was targeted by IL-18BP. In these studies, species-specific
normal IgG and Fc served as respective controls. (i) LDH activity in equal amounts of
culture supernatants in the presence of neutralizing antibodies or IL-18BP-Fc to determine
cell death. Treatment with hydrogen peroxide (100 μM) served as a positive control. Data
represent mean ±SE of 6 (mRNA expression, cytokine secretion, proliferation and
migration) independent experiments. Western blotting in b,c,i, and j were a representative of
three independent experiments. *P<at least 0.01 versus untreated; †P<0.05 versus IL-17A.
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Figure 3. IL-17A induces NLRP3 expression via TRAF3IP2, NF-κB, AP-1 and p38 MAPK.
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(a) Experimental design to analyze IL-17A-mediated NLRP3 expression. (b) IL-17A
induces NLRP3 expression in part via TRAF3IP2. Quiescent SMC were treated with IL-17A
for 6 h and analyzed for NLRP3 expression by Western blotting. In a subset of experiments,
TRAF3IP2 was silenced as in Fig. 1A. In the knockdown experiments, GFP served as a nontargeting control. Data from three independent experiments is summarized on the right. (c)
NF-κB p65 and AP-1 c-Jun are involved in IL-17A-induced NLRP3 expression. Both p65
and c-Jun were silenced by lentiviral transduction of validated shRNA in SMC. GFP served
as a non-targeting control. Data from three independent experiments is summarized on the
right. Knockdown of p65 and c-Jun was confirmed by Western blotting as shown in the right
most panels. In those knockdown studies, ASK1 served as a non-targeting control. (d)
Pharmacological inhibition of p38 MAPK inhibits IL-17A-induced NLRP3 expression. p38
MAPK was targeted by SB239063 or SB202190. DMSO served as a solvent control. Data
from three independent experiments is summarized on the right. (e) Silencing p65 or c-Jun
or pharmacological inhibition of p38 MAPK did not affect cell viability. Cell death was
analyzed by quantifying LDH activity in culture supernatants at 8 h by a quantitative
colorimetric assay. Data represent mean ±SE of 3 independent experiments. *P<at least 0.01
versus untreated; †P<0.05 versus IL-17A.
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Figure 4. IL-17A enhances the expression and activity of caspase-1.

(a) Experimental design. (b) MCC950 and dapansutrile inhibit IL-17A-induced NLRP3
expression. Quiescent SMC were treated with MCC950 or dapansutrile prior to IL-17A
addition. Ethyl alcohol (EtOH) served as a solvent control. NLRP3 expression at 6 h was
analyzed by Western blotting. Data from three independent experiments is summarized on
the right. (c,d,e) Targeting NLRP3 inflammasome by MCC950 or dapansutrile inhibit
caspase-1 cleavage (c) or activity (d) without compromising cell survival (e). The
experiments in c-e were performed three times, and a representative Western blot is shown.
However, data from three independent experiments is summarized in the respective right
hand panel. *P<at least 0.05 versus untreated; †P<at least 0.05 versus IL-17A.
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Figure 5. Inhibition of NLRP3 and caspase-1 attenuate IL-17A-induced IL-1β and IL-18
secretion, and SMC migration and proliferation.
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(a) Experimental design. (b) Targeting caspase-1 by a specific inhibitor or pan-caspase
inhibitor or pharmacological inhibition of NLRP3 inflammasome or its knockdown attenuate
IL-17A-induced IL-1β (b) or IL-18 (c) secretion. Cytokine levels in culture supernatants at
24 h were quantified by ELISA. Knockdown of NLRP3 was confirmed by Western blotting
(Fig. 5C, right hand panel). In the knockdown studies, MyD88 served as a non-targeting
control. (d,e,f) Targeting caspase-1 or NLRP3 attenuates IL-17A-induced SMC proliferation
and migration, without inducing cell death. Cell death was analyzed by quantifying LDH
activity at 8 h in equal amounts of culture supernatants by a quantitative colorimetric assay.
H2O2 served as a positive control. Data represent mean ±SE of 6 (b,c,d,e) or 3 (f)
independent experiments. P<0.01 versus untreated; †P<0.05 versus IL-17A.
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Figure 6. Empagliflozin inhibits IL-17A-induced oxidative stress and TRAF3IP2 expression
without affecting cell viability.
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(a) Experimental design. (b) SMC express SGLT2 transcript. Quiescent SMC were analyzed
for SGLT2 mRNA expression by RT-qPCR, and normalized to 18S expression. SGLT2
protein levels were analyzed by Western blotting. Human kidney homozenates and HL-2
cleared cell lysates served as positive controls. (c, d) IL-17A induces SGLT2 mRNA (c) and
protein (d) expression in a time-dependent manner. Quiescent SMC were incubated with
IL-17A for the indicated periods. SGLT2 mRNA expression was analyzed by RT-qPCT and
protein levels by Western blotting. (e) Experimental design to investigate empagliflozin’s
effects. (f, g) Empagliflozin inhibits IL-17A-induced superoxide (f) and hydrogen peroxide
(g) production. Quiescent SMC were treated with empagliflozin ranging from 0.1 to 5 μM
for 15 min prior to IL-17A addition. Superoxide production was analyzed at 15 min by
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lucigenin-enhanced chemiluminescence assay (f). In experiments analyzing hydrogen
peroxide production (g), empagliflozin was used at a concentration of 1μM for15 min prior
to IL-17A addition for 30 min. Hydrogen peroxide production was analyzed by Amplex Red
assay. (h) Empagliflozin inhibits IL-17A-induced TRAF3IP2 expression. Quiescent SMC
treated as in (g) were analyzed for TRAF3IP2 expression at 1 h by Western blotting. (i)
Empagliflozin did not affect cell survival. Cell death was analyzed by quantifying LDH
activity in equal amounts of culture supernatants using a quantitative colorimetric assay.
Data represent mean ±SE of 6 (c,f,g,i) or 3 (b,d,h) independent experiments. P<0.01 versus
untreated; †P<at least 0.05 versus IL-17A.
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Figure 7. Empagliflozin inhibits IL-17A-induced NLRP3 inflammasome expression, caspase-1
activation, cytokine secretion, and SMC proliferation and migration.
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(a) Experimental design. (b) Empagliflozin dose-dependently inhibits IL-17A-induced
NLRP3 expression. Quiescent SMC were incubated with empagliflozin at the indicated
concentrations for 15 min prior to IL-17A addition. DMSO served as a solvent control.
NLRP3 expression was analyzed at 6h by Western blotting. (c) Empagliflozinn does not
affect cell viability, as evidenced by no significant changes in LDH activity at 8 h in equal
amounts of culture supernatants. (d,e) Empagliflozin inhibits caspase-1 activation. SMC
treated as in (a) but with 1μM empagliflozin and analyzed for cleaved caspase-1 levels at 6h
by Western blotting and its activity by a colorimetric assay. (f,g) Empagliflozin inhibits
IL-17A-induced cytokine secretion. Quiescent SMC treated with empagliflozingn (1 μM for
15 min) prior to IL-17A addition were analyzed for secreted cytokine levels at 24h by
ELISA. Secreted cytokine levels were also analyzed by Western blotting using equal
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amounts of concentrated culture supernatants. Tubulin in whole cell lysates served as a
loading control. (h,i) Empagliflozin inhibits IL-17A-induced SMC proliferation and
migration. Quiescent SMC were incubated with 1 μM empagliflozin for 15 min prior to
IL-17A addition. Cell proliferation was quantified at 48h using the CyQUANT assay. SMC
migration was analyzed after 18h using the Boyden chamber assay. Data represent mean
±SE of 3 (b,c,d, and insets in f, g) or 6 (f-i) independent experiments. *P<at least 0.01 versus
untreated; †P<0.05 versus IL-17A.
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Figure 8. Silencing SGLT2 attenuates IL-17A-induces cytokine secretion, and SMC proliferation
and migration.
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(a) Experimental design. (b) SGLT2 knockdown. SMC transduced with lentiviral SGLT2
shRNA for 48 h were analyzed for SGLT2 expression by Western blotting. MyD88 served as
an off target. (c,d) SGLT2 knockdown attenuates empagliflozin-mediated inhibition of
IL-17-induced IL-1b (c) and IL-18 (d) secretion. SMC silenced for SGLT2 were made
quiescent, treated with expagliflozin (1mM for 15 min) and then exposed to IL-17A for 24
h. Secreted cytokine levels were analyzed by ELISA using equal amounts of culture
supernatants. Secreted cytokine levels were also analyzed by Western blotting using equal
amounts of concentrated culture supernatants (insets). (e,f) SGLT2 knockdown attenuates
empagliflozin-mediated inhibition of SMC proliferation (e) and migration (f). SMC silenced
for SGLT2 treated as in c and d, but for 48 h (e) and 18 h (f) were analyzed for proliferation
(e) and migration (f). Proliferation was analyzed by the CyQUANT assay and migration by
the Boyden chamber assay. Data represent mean ±SE of 3 (b,insets in c and d) or 6 (c,d,e,f)
independent experiments. *P<at least 0.05 versus untreated; †P<0.05 versus IL-17A;
§P<0.05 versus SGLT2 knockdown.
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Figure 9. A working model describing the molecular mechanisms underlying IL-17A-induced
SMC migration and proliferation, and those targeted by empagliflozin.
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IL-17A induces primary human aortic smooth muscle cell migration and proliferation via
TRAF3IP2-dependent ROS generation, NLRP3 expression, caspase-1 activation, and
proinflammatory and pro-mitogenic IL-1β and IL-18 expression. Transduction of short
hairpin RNA (shRNA) by adeno- or lentivirus, pharmacological or peptide inhibitors and
neutralizing antibodies targeted TRAF3IP2, NF-κB, AP-1, NOX2, NOX4, NLRP3,
caspase-1, IL-1β and IL-18. Importantly, SMC express SGLT2, and the SGLT2 inhibitor
empagliflozin (EMPA) attenuated IL-17A-induced maladaptive changes by exerting antioxidant, anti-inflammatory, anti-migratory and anti-mitogenic effects without inducing cell
death. It is also plausible that empagliflozin may exert its beneficial inhibitory effects in part
via NHE (in green). Together, these mechanistic in vitro results suggest the therapeutic
potential of EMPA in vascular proliferative diseases.
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